Skip to main content
. 2023 Feb 22;14:993. doi: 10.1038/s41467-023-36637-3

Fig. 5. Drug repurposing for precursor T cell acute lymphoblastic leukemia (Pre-T ALL).

Fig. 5

a UMAP plots of all cells from 3 normal controls and 2 Pre-T ALL samples. b UMAP plots of T cell clusters from normal controls and Pre-T ALL samples. c Pathway enrichment analysis (leukemia vs normal) for each T cell cluster. P-values were determined by two-sided Fisher’s exact test and were adjusted by BH FDR. d The overall drug score and drug score in each Pre-T ALL patient, among top-ranked significant drugs (FDR < 0.05). Drug approved for leukemia treatment by the FDA is tretinoin. e The drug candidate tretinoin, its target genes, pathways, and single-cell clusters. All labels and their annotations are the same as Fig. 4f. P-values were determined by two-sided Fisher’s exact test and were adjusted by BH FDR. Source data are provided as a Source Data file.